A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation.

Trial Profile

A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atrial Fibrillation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACT-5; ACT-V
  • Sponsors Cardiome Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2010-018374-20).
    • 21 Oct 2010 This trial is expected to be reinitiated after consultation with the trial's independent DSMB and the US FDA. The FDA have requested full data regarding the serious adverse event in South America, according to a Cardiome media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top